- NCT00526877
- Primary Citation Not Available
- Data Specification Not Available
Trial Information
Generic NameRisperidoneProduct NameRISPERDAL CONSTA®Therapeutic AreaBehaviors and Mental DisordersEnrollment31% Female35%% WhiteN/A
Product ClassAtypical AntipsychoticsSponsor Protocol NumberRISSCH4119 (RISC-TWN-MA10)Data PartnerJohnson & JohnsonCondition StudiedSchizophreniaMean/Median Age (Years)37.6
Supporting Documentation
- Clinical Study Report Available
Additional Information
Please note: individual participant-level data are not available for this trial. Only the clinical study report is available.
Approved Data Requests Associated with this Trial
- 2024-0556 : Heterogeneity of treatment effects during guaranteed antipsychotic maintenance treatment in schizophrenia as a window into the mechanisms of treatment
- 2024-0008 : Sex differences in antipsychotic efficacy and side-effects in adults with acute exacerbations of schizophrenia: an individual-participant network meta-analysis
- 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment ? An individual participant data meta-analysis
- 2021-4705 : Inflammation and the Metabolic Syndrome in Psychosis
- 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.